This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Menu
Close
Prescribing Information for TicoVac® (Tick-Borne Encephalitis Vaccine (whole Virus Inactivated)) can be found here. Information about adverse event reporting can be found at the bottom of the page.
Tick-borne encephalitis (TBE) is an infection of the central nervous system that affects the brain, spinal cord and membranes around them and can be more severe in some individuals.1
TBE virus belongs to a closely related group of viruses called flaviviruses.2 These include yellow fever, dengue and Japanese encephalitis. There are 3 subtypes of TBE virus: European/Western, Siberian and Far Eastern.1
People can develop TBE if they have been bitten by a tick that is infected with the TBE virus.1
Between 10,000 to 12,000 clinical cases of TBE are reported each year globally.2
1 in 3 people infected with the TBE virus will develop long-term neurological complications.1
TicoVac® and TicoVac Junior® (tick-borne encephalitis vaccine suspension for injection in a prefilled syringe) are vaccines indicated for the active (prophylactic) immunization against tick-borne encephalitis (TBE) of persons of 16 years of age and older and children aged between 1 and 15 years.12,13
Both are to be given on the basis of official recommendations regarding the need for, and timing of, vaccination against TBE. 12,13
Transmission of TBE to humans usually takes place during a tick bite through the saliva of an infected tick, although unpasteurised dairy products from infected animals can also pose a risk.1
Ticks are the main vectors and reservoir hosts of the TBE virus. Ticks can get infected with TBE through co-feeding, feeding on a viremic host or occasionally transovarially from infected females to eggs.1
Not all ticks spread TBE. But in highly endemic† areas up to 40% of ticks carry the virus, although prevalence varies considerably by region3, see ‘Who is at risk?’ section below.
† Endemic areas are where an infection in a population is constantly maintained at a controllable level.
Location
TBE has been reported in over 35 countries. TBE infected ticks can be found across parts of Europe, including some parts of the UK, North Africa and Asia.3,4
Reports of TBE are generally at altitudes lower than 1500 metres. However, ticks have been noted at higher altitudes, thought to be as a result of climate change.5
Time of year
Ticks are typically active when temperatures are above 6º Celsius, usually from March to November. However, the tick season can vary each year depending on the climate.1
Activity
Ticks live outside and near the ground but can be found both within or outside cities, in parks, gardens and forests.5
Outdoor activities can put you at risk of coming into contact with ticks; for example, if you take part in activities in grassy areas where ticks are commonly found.5
For most people infected with the TBE virus, there are no symptoms but if there are, they usually appear up to 2 weeks after being bitten and follow 2 phases:6
1st Phase: Flu-like symptoms for 2-7 days followed by an asymptomatic period for 2-10 days. Fever, headache, tiredness, nausea, muscle pain.
2nd Phase: Involving the neurological system with symptoms of meningitis and/or encephalitis. High fever, headache, fatigue, nausea, vomiting and vertigo.
Most people infected recover fully, but 35 to 58% of people with TBE develop post-encephalitic syndrome (PES), which causes serious long-term complications including paralysis.6
The European TBE subtype has a mortality rate of 0.5-2% - this means that up to 1 in every 50 people who develop symptoms upon contracting this subtype of TBE will die from this infection. The Siberian subtype is associated with a mortality rate of 1-3% and the Far Eastern subtype has mortality rates of up to 35%.
There is no specific treatment for TBE, and unlike Lyme disease (which is also transmitted by ticks) it cannot be treated with antibiotics.7,9
Therefore, TBE can only be treated symptomatically through:9
• Monitoring of vital functions, if necessary in an ICU
• Maintaning the water and electrolyte balance
• Ensuring sufficient caloric intake
• Administration of analgesics and antipyretics
• If necessary, administration of anticonvulsive agents
• Using physiotherapy for paralysed limbs to prevent muscle atrophy
• Rehabilitation
Countries with risk of contracting TBE3,10
There are steps to help to prevent TBE both before and during travels to countries where there is a risk of TBE. Vaccination before travel is a proven way to help prevent TBE infection.11
You should recommend vaccination against TBE to anyone who may be at risk of TBE through their work or are travelling to the above TBE risk areas and participating in activities which increase the risk of virus exposure such as walking, hiking, cycling and camping.3,11
There are additional steps that help to protect individuals from TBE infection and avoid tick bites:4
Browse and register for speaker programs
View materials for you and your patients
Find videos and on-demand webinars
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024